Trillium Therapeutics (Trillium Therapeutics) Other Income (Expense) : $0.08 Mil (TTM As of Sep. 2021)

View and export this data going back to 2009. Start your Free Trial

What is Trillium Therapeutics Other Income (Expense)?

Trillium Therapeutics's other income expense for the Trillium Therapeutics's pretax income for the three months ended in Sep. 2021 was $0.01 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2021 was $0.08 Mil.

Trillium Therapeutics Other Income (Expense) Historical Data

The historical data trend for Trillium Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trillium Therapeutics Other Income (Expense) Chart

Trillium Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Other Income (Expense)

Get a 7-Day Free Trial

-1.51

-3.77

2.71

-6.36

0.20

Trillium Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Other Income (Expense)	Get a 7-Day Free Trial															0.01	0.09	-0.04	0.01	0.01

Trillium Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.

Trillium Therapeutics (NAS:TRIL) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Trillium Therapeutics (Trillium Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trillium Therapeutics Inc (NAS:TRIL) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 CambridgePark Drive, Suite 510, Cambridge, MA, USA, 02140

Website

https://www.trilliumtherapeutics.com

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.